Patients with persistent, relapsed or progressing malignancy after nonmyeloablative allogeneic transplantation; persistent disease will be defined as a failure to achieve a response as compared to baseline [clinicaltrials_resource:14cc7516ba8997ef11ce82cee47867bd]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Patients with persistent, relapsed or progressing malignancy after nonmyeloablative allogeneic transplantation; persistent disease will be defined as a failure to achieve a response as compared to baseline [clinicaltrials_resource:14cc7516ba8997ef11ce82cee47867bd]
Bio2RDF identifier
14cc7516ba8997ef11ce82cee47867bd
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:14cc7516ba8997ef11ce82cee47867bd
identifier
clinicaltrials_resource:14cc7516ba8997ef11ce82cee47867bd
title
Patients with persistent, rela ...... sponse as compared to baseline
@en
type
label
Patients with persistent, rela ...... c7516ba8997ef11ce82cee47867bd]
@en